A proof-of-concept randomized controlled study of gabapentin: Effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults

Neuropsychopharmacology

Volumn 37, Issue 7, 2012, Pages 1689-1698

  Mason, Barbara J ^a   Crean, Rebecca ^a   Goodell, Vivian ^a   Light, John M ^b   Quello, Susan ^a   Shadan, Farhad ^c   Buffkins, Kimberly ^a   Kyle, Mark ^c   Adusumalli, Murali ^c   Begovic, Adnan ^c   Rao, Santosh ^c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b OREGON RESEARCH INSTITUTE   (United States)

^c SCRIPPS GREEN HOSPITAL   (United States)

Author keywords

addiction treatment; cannabis dependence; executive function; gabapentin; marijuana withdrawal; randomized controlled trial

Indexed keywords

GABAPENTIN; PLACEBO;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; CANNABIS ADDICTION; CHECKLIST; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; COUNSELING; DELIS KAPLAN EXECUTIVE FUNCTION SYSTEM; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EXECUTIVE FUNCTION; FEMALE; HUMAN; INTERVIEW; MALE; MARIJUANA WITHDRAWAL CHECKLIST; NEUROLOGIC EXAMINATION; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIMELINE FOLLOWBACK INTERVIEW; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AMINES; CALCIUM CHANNEL BLOCKERS; CANNABIS; COUNSELING; CYCLOHEXANECARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 84861192052     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.14     Document Type: Article

References (47)

1. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision. American Psychiatric Press: Washington, DC. .
2. Beck AT, Steer RA, Ball R, Ranieri W (1996). Comparison of beck depression inventories -IA and -II in psychiatric outpatients. J Pers Assess 67: 588-597. (Pubitemid 26382973)
3. Bolla KI, Lesage SR, Gamaldo CE, Neubauer DN, Wang NY, Funderburk FR et al (2010). Polysomnogram changes in marijuana users who report sleep disturbances during prior abstinence. Sleep Med 11: 882-889.
4. Budney AJ, Moore BA, Vandrey RG, Hughes JR (2003). The time course and significance of cannabis withdrawal. J Abnorm Psychol 112: 393-402. (Pubitemid 36959365)
5. Budney AJ, Novy PL, Hughes JR (1999). Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 94: 1311-1322. (Pubitemid 29433790)
6. Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursac Z (2008). Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J Subst Abuse Treat 35: 362-368.
7. Buysse DJ, Reynolds 3rd CF, Monk TH, Berman SR, Kupfer DJ (1989). The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 28: 193-213. (Pubitemid 19144991)
8. Caravati EM (2003). Marijuana and other cannabinoids. In: Dart RC (ed). Medical Toxicology, 3rd edn. Lippincott Williams & Wilkins: Philadelphia, PA. .
9. Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR (2009). A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict 18: 53-64.
10. Copersino ML, Boyd SJ, Tashkin DP, Huestis MA, Heishman SJ, Dermand JC et al (2006). Cannabis withdrawal among nontreatment- seeking adult cannabis users. Am J Addict 15: 8-14. (Pubitemid 43207184)
11. Crean RD, Crane NA, Mason BJ (2011). An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 5: 1-8.
12. Delis D, Kramer J, Kaplan E (2001). Manual for the Delis-Kaplan Executive Function System (D-KEFS). Psychological Corporation: San Antonio, TX. .
13. Donovan DM, Bigelow GE, Brigham GS, Carroll KM, Cohen AJ, Gardin JG et al (2011). Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction (e-pub ahead of print). .
14. Fals-Stewart W, O'Farrell TJ, Freitas TT, McFarlin SK, Rutigliano P (2000). The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol 68: 134-144. (Pubitemid 30120958)
15. Fraser AD, Worth D (1999). Urinary excretion profiles of 11-nor-9- carboxy-delta9 tetrahydrocannabinol: a delta9-THCCOOH to creatinine ratio study. J Anal Toxicol 23: 531-534. (Pubitemid 29473409)
16. Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK (1998). Gabapentin treatment of mood disorders: a preliminary study. J Clin Psy 59: 426-429. (Pubitemid 28391565)
17. Goldstein RZ, Volkow ND (2002). Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159: 1642-1652.
18. Gueorguieva R, Krystal JH (2004). Move over ANOVA: progress in analyzing repeated- measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 61: 310-317. (Pubitemid 38295833)
19. Harden CL, Lazar LM, Pick LH, Nikolov B, Goldstein MA, Carson D et al (1999). A beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia 40: 1129-1134. (Pubitemid 29372629)
20. Huestis MA, Cone EJ (1998). Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol 22: 445-454. (Pubitemid 28457817)
21. Karam-Hage M, Brower KJ (2000). Gabapentin treatment for insomnia associated with alcohol dependence. Am J Psy 157: 151.
22. Koob GF, Kandel DB, Volkow ND (2008). Psychiatric pathophysiology: addiction. In: Tasman A, Kay J, Lieberman J, First MB, Maj M (eds). Psychiatry, 3rd edn. John Wiley & Sons: West Sussex, England. .
23. Koob GF, Le Moal M (2005). Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nature Neurosci 8: 1442-1444. (Pubitemid 41573653)
24. Koob GF, Le Moal M (2008). Addiction and the brain antireward system. Annu Rev Psychol 59: 29-53.
25. Koob GF, Volkow ND (2010). Neurocircuitry of addiction. Neuropsychopharmacology 35: 217.
26. Laird NM, Ware JH (1982). Random-effects models for longitudinal data. Biometrics 38: 963-974.
27. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV (2011). Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 116: 142-150.
28. Levin FR, McDowell D, Evans SM, Nunes E, Akerele E, Donovan S et al (2004). Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict 13: 21-32. (Pubitemid 38294861)
29. Levine J, Schooler NR (1986). SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22: 343-381. (Pubitemid 16043808)
30. Lo HS, Yang CM, Lo HG, Lee CY, Ting H, Tzang BS (2010). Treatment effects of gabapentin for primary insomnia. Clin Neuropharmacol 33: 84-90.
31. Maldonado R, Berrendero F, Ozaita A, Robledo P (2011). Neurochemical basis of cannabis addiction. Neuroscience 181: 1-17.
32. Mason BJ, Light JM, Williams LD, Drobes DJ (2009). Proofof- concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol 14: 73-83.
33. McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, Wahlquist AE, Simpson SA et al (2009). A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend 105: 132-138.
34. McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, White KG, Brady KT (2010). A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict 19: 481-489.
35. Neurontin (gabapentin) [package insert LAB-0106-9.0]. Pfizer, New York. Revised January 2007.
36. Nordstrom BR, Levin FR (2007). Treatment of cannabis use disorders: a review of the literature. Am J Addict 16: 331-342. (Pubitemid 47450754)
37. Norusis MJ (2008). SPSS Statistics 17.0 Advanced Statistical Procedures Companion. Prentice Hall Inc.: Upper Saddle River, NJ.
38. Roberto M, Gilpin NW, O'Dell LE, Cruz MT, Morse AC, Siggins GR et al (2008). Cellular and behavioral interactions of gabapentin with alcohol dependence. J Neurosci 28: 5762-5771.
39. Rodriguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F (1997). Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276: 2050-2054. (Pubitemid 27443612)
40. Salinsky MC, Storzbach D, Spencer DC, Oken BS, Landry T, Dodrill CB (2005). Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 64: 792-798. (Pubitemid 40316314)
41. Sills GJ (2006). The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 6: 108-113. (Pubitemid 43103827)
42. Smith ML, Barnes AJ, Huestis MA (2009). Identifying new cannabis use with urine creatinine- normalized THCCOOH concentrations and time intervals between specimen collections. J Anal Toxicol 33: 185-189.
43. Sofuoglu M, Sugarman DE, Carroll KM (2010). Cognitive function as an emerging treatment target for marijuana addiction. Exp Clin Psychopharmacol 18: 109-119.
44. Stephens RS, Roffman RA, Curtin L (2000). Comparison of extended vs brief treatments for marijuana use. J Consult Clin Psychol 68: 898-908.
45. United Nations: New York, NY. West BT (2009). Analyzing longitudinal data with the linear mixed models procedure in SPSS. Eval Health Prof 32: 207-228.
46. Wilkinson GS, Robertson GJ (2006). Wide Range Achievement Test-4 Professional Manual. Psychological Assessment Resources, Inc: Lutz, FL. .
47. Xue X, Gange SJ, Zhong Y, Burk RD, Minkoff H, Massad LS et al (2010). Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev 19: 159-169.